JP7387912B2 - 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ - Google Patents

免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ Download PDF

Info

Publication number
JP7387912B2
JP7387912B2 JP2022554243A JP2022554243A JP7387912B2 JP 7387912 B2 JP7387912 B2 JP 7387912B2 JP 2022554243 A JP2022554243 A JP 2022554243A JP 2022554243 A JP2022554243 A JP 2022554243A JP 7387912 B2 JP7387912 B2 JP 7387912B2
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
ctla
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022554243A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021228978A5 (https=
JP2023524359A (ja
JP2023524359A5 (https=
Inventor
カーランド，ジョン
ネグロ，アレハンドラ
チャン，シャオ－チュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2023524359A publication Critical patent/JP2023524359A/ja
Publication of JPWO2021228978A5 publication Critical patent/JPWO2021228978A5/ja
Publication of JP2023524359A5 publication Critical patent/JP2023524359A5/ja
Priority to JP2023191381A priority Critical patent/JP2024016209A/ja
Application granted granted Critical
Publication of JP7387912B2 publication Critical patent/JP7387912B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2022554243A 2020-05-12 2021-05-12 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ Active JP7387912B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023191381A JP2024016209A (ja) 2020-05-12 2023-11-09 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023554P 2020-05-12 2020-05-12
US63/023,554 2020-05-12
PCT/EP2021/062695 WO2021228978A1 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191381A Division JP2024016209A (ja) 2020-05-12 2023-11-09 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ

Publications (4)

Publication Number Publication Date
JP2023524359A JP2023524359A (ja) 2023-06-12
JPWO2021228978A5 JPWO2021228978A5 (https=) 2023-06-26
JP2023524359A5 JP2023524359A5 (https=) 2023-06-26
JP7387912B2 true JP7387912B2 (ja) 2023-11-28

Family

ID=75977756

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022554243A Active JP7387912B2 (ja) 2020-05-12 2021-05-12 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ
JP2023191381A Pending JP2024016209A (ja) 2020-05-12 2023-11-09 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023191381A Pending JP2024016209A (ja) 2020-05-12 2023-11-09 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ

Country Status (12)

Country Link
US (3) US20210355224A1 (https=)
EP (1) EP4021940A1 (https=)
JP (2) JP7387912B2 (https=)
KR (1) KR20230009354A (https=)
CN (1) CN114729054A (https=)
AU (3) AU2021269832B2 (https=)
BR (1) BR112022021893A2 (https=)
CA (1) CA3158607A1 (https=)
IL (2) IL311936A (https=)
MX (1) MX2022006728A (https=)
TW (2) TWI870592B (https=)
WO (1) WO2021228978A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260077026A1 (en) * 2022-09-07 2026-03-19 The University Of Chicago Methods for treating cancer with hyperactive adar enzymes
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트
WO2025256641A1 (zh) * 2024-06-13 2025-12-18 江苏恒瑞医药股份有限公司 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222949A1 (en) 2017-06-01 2018-12-06 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CA2484052C (en) 2002-04-11 2011-06-14 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
US7135180B2 (en) 2002-04-11 2006-11-14 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
KR20050088175A (ko) 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
TWI716362B (zh) * 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
EP3277318A1 (en) * 2015-04-01 2018-02-07 Medimmune Limited Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer
KR102664891B1 (ko) * 2016-06-20 2024-05-13 에프-스타 테라퓨틱스 리미티드 Pd-l1 및 lag-3에 결합하는 결합 분자
MX2019003569A (es) * 2016-09-27 2020-07-22 Oncologie Inc Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.
JP2020515637A (ja) * 2017-04-03 2020-05-28 オンコロジー、インコーポレイテッド 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法
RU2019138742A (ru) * 2017-05-26 2021-06-28 Бруин Байосаенсис, Инк. Средства для химиоэмболизации
WO2019241742A1 (en) * 2018-06-14 2019-12-19 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
AU2019285344A1 (en) * 2018-06-15 2020-12-10 Mina Therapeutics Limited Combination therapies comprising C/EBP alpha saRNA

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222949A1 (en) 2017-06-01 2018-12-06 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUSSIER, D.M. et al.，J Immunother Cancer，2015年，Vol. 3, Article No. 21，pp. 1-11

Also Published As

Publication number Publication date
EP4021940A1 (en) 2022-07-06
TW202535468A (zh) 2025-09-16
AU2021269832A1 (en) 2022-05-19
WO2021228978A1 (en) 2021-11-18
US20240239893A1 (en) 2024-07-18
CN114729054A (zh) 2022-07-08
JP2023524359A (ja) 2023-06-12
AU2024202963B2 (en) 2025-11-20
MX2022006728A (es) 2022-06-09
KR20230009354A (ko) 2023-01-17
AU2024202963A1 (en) 2024-05-30
CA3158607A1 (en) 2021-11-18
IL297640A (en) 2022-12-01
TWI870592B (zh) 2025-01-21
US20210355224A1 (en) 2021-11-18
TW202207976A (zh) 2022-03-01
AU2021269832B2 (en) 2024-09-19
IL311936A (en) 2024-06-01
AU2024266949A1 (en) 2024-12-19
BR112022021893A2 (pt) 2022-12-20
US20220363762A1 (en) 2022-11-17
JP2024016209A (ja) 2024-02-06

Similar Documents

Publication Publication Date Title
JP2024016209A (ja) 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ
CN114746117B (zh) 抗dll3药剂的给药方案
EP3137502A1 (en) Humanized antibodies against ceacam1
US20240148740A1 (en) Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
JP2023540255A (ja) 肝細胞癌のためのｌａｇ－３アンタゴニスト療法
US20240207431A1 (en) Use of antibody-drug conjugate in combination with immune checkpoint inhibitor in treatment of urothelial cancer
CN109793892B (zh) 一种抗pd-1抗体在制备治疗食管癌的药物中的用途
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
US20240317854A1 (en) Methods for treating cancer with anti-ilt3 antibodies
EA050171B1 (ru) Способы и комбинации для лечения рака с применением антител, являющихся ингибиторами иммунных контрольных точек
BR122025009416A2 (pt) Combinação farmacêutica compreendendo um anticorpo anti-pd-l1 e um anticorpo anti-ctla-4, seu uso, uso de um anticorpo anti-pd-l1, uso de um anticorpo anti-ctla-4 e composição
WO2025087358A1 (zh) 抗体药物偶联物用于治疗癌症的方法
WO2025242190A1 (zh) 抗tigit抗体和抗pd-1抗体联合治疗肿瘤
WO2025002263A1 (zh) 治疗组合及其用途和治疗方法
CN121868478A (zh) 包含cd20/cd47阻断双功能融合蛋白的组合及其应用
EA051880B1 (ru) Схема введения доз для средств на основе антитела к dll3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230616

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231115

R150 Certificate of patent or registration of utility model

Ref document number: 7387912

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150